The SARS-CoV ferret model in an infection–challenge study

Phase I human clinical studies involving therapeutics for emerging and biodefense pathogens with low incidence, such as the severe acute respiratory syndrome coronavirus (SARS-CoV), requires at a minimum preclinical evaluation of efficacy in two well-characterized and robust animal models. Thus, a f...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Yong-Kyu, Ali, Georgia D., Jia, Fuli, Li, Qianjun, Kelvin, David, Couch, Ronald C., Harrod, Kevin S., Hutt, Julie A., Cameron, Cheryl, Weiss, Susan R., Jonsson, Colleen B.
Formato: Texto
Lenguaje:English
Publicado: Elsevier Inc. 2008
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831213/
https://www.ncbi.nlm.nih.gov/pubmed/18234270
http://dx.doi.org/10.1016/j.virol.2007.12.032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831213/
https://www.ncbi.nlm.nih.gov/pubmed/18234270
http://dx.doi.org/10.1016/j.virol.2007.12.032

Ejemplares similares